Factor 8 deficiency, acquired: Clinical Trials

6 trials for Factor 8 deficiency, acquired, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 active not recruiting, 1 terminated, 1 unknown. 6 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Completed 3, Active not recruiting 1, Terminated 1, Unknown 1
Phase 33Completed 2, Terminated 1

Follow Factor 8 deficiency, acquired: new trials by email Literature Review of Factor 8 deficiency, acquired trials Research Report on Factor 8 deficiency, acquired

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Emicizumab in Patients With Acquired Hemophilia A
emicizumab - Acquired Hemophilia A
Phase 2Active not recruitingUniversity of Washington512022-08-312025-11-05
Study of TAK-672 in Participants With Acquired Hemophilia A
TAK-672 - Acquired Hemophilia A
Phase 2 / Phase 3CompletedTakeda52021-04-092024-12-02
Emicizumab in Acquired Hemophilia A
Emicizumab Injection - Hemophilia A, Acquired
Phase 2CompletedGWT-TUD GmbH472021-03-232023-01-09
Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
Bortezomib, Rituximab - Acquired Hemophilia A
Phase 2UnknownPeking Union Medical College Hospital222018-10-102018-11-23
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
OBI-1 - Acquired Hemophilia A
Phase 2 / Phase 3CompletedBaxalta now part of Shire292010-11-102021-05-13
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
Rituxan, prednisone - Hemophilia A
Phase 2 / Phase 3TerminatedGeorgetown University22006-04-012017-02-10

Narrower conditions

Hemophilia A (2)  ·  Blood Coagulation Disorders (1)  ·  Coagulation Protein Disorders (1)  ·  Hematologic Diseases (1)  ·  Hemorrhagic Disorders (1)

Broader conditions

Blood Coagulation Disorders, Inherited (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Genetic Diseases, Inborn (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Blood Coagulation Disorders (1)  ·  Coagulation Protein Disorders (1)  ·  Hematologic Diseases (1)  ·  Hemorrhagic Disorders (1)

Interventions

Rituximab (2)  ·  emicizumab (2)  ·  Adrenal Cortex Hormones (1)  ·  Bortezomib (1)  ·  Factor VIII (1)  ·  Prednisone (1)

Sponsors

Baxalta now part of Shire (1)  ·  GWT-TUD GmbH (1)  ·  Georgetown University (1)  ·  Peking Union Medical College Hospital (1)  ·  Takeda (1)  ·  University of Washington (1)

Countries

United States (2)  ·  Austria (1)  ·  Canada (1)  ·  China (1)  ·  Germany (1)  ·  India (1)  ·  Japan (1)  ·  United Kingdom (1)

Top investigators

Andreas Tiede, Prof. Dr. (1)  ·  Craig Kessler, MD (1)  ·  Rebecca Kruse-Jarres, MD, MPH (1)  ·  Tienan Zhu (1)

Results publications

PMID 25623166, PMID 29296693, PMID 37858328, PMID 39228858, PMID 40795229, PMID 42290320